Dupixent Lawsuit Attorneys

Skin Cancer (CTCL) Claims Linked to Dupixent (Dupilumab)

If you or a loved one were diagnosed with cutaneous T-cell lymphoma (CTCL) after using Dupixent®, you may be eligible to file a lawsuit and seek financial compensation.

At Salenger, Sack, Kimmel & Bavaro, LLP, we are actively investigating Dupixent cancer lawsuits involving patients who developed—or experienced worsening—T-cell lymphomas after taking this medication.

What Is Dupixent (dupilumab)?

Dupixent (dupilumab) is a prescription injectable drug used to treat:

• Eczema (atopic dermatitis)
• Asthma
• Chronic sinusitis with nasal polyps
• Eosinophilic esophagitis

Manufactured by Sanofi and Regeneron Pharmaceuticals, Dupixent works by targeting inflammation in the immune system.

While effective for many patients, recent studies have raised concerns about a possible link between Dupixent and certain cancers, particularly CTCL.

Dupixent and CTCL (Skin Cancer Risk)

Cutaneous T-cell lymphoma (CTCL) is a rare form of cancer that affects the skin and immune system.

Research suggests that Dupixent may:

• Trigger or accelerate undiagnosed CTCL
• Mask early symptoms, delaying proper diagnosis
• Lead to worsening disease progression in some patients

This is especially concerning for patients initially diagnosed with eczema, as early CTCL can closely resemble inflammatory skin conditions.

For background on CTCL, visit the National Cancer Institute (NCI).

Common Symptoms of CTCL:

• Persistent rash or scaly skin patches
• Skin lesions that worsen over time
• Severe itching
• Swollen lymph nodes
• Fatigue or unexplained weight loss

Scientific Evidence Linking Dupixent to Cancer

Recent peer-reviewed studies have reported increased risks:

• 2024 (JAMA Dermatology): ~3x higher risk of CTCL
• 2024 (TriNetX data study): ~3.5x increased risk
• 2025 study: Up to 4.5x higher risk of CTCL and significantly increased risk of other T-cell lymphomas
• Journal of the American Academy of Dermatology (JAAD): Dupixent may “unmask” hidden lymphomas

These findings have led to growing concern among physicians and researchers and calls for closer monitoring of patients.

Current Status of Dupixent Litigation (2026 Update)

As of early 2026, Dupixent lawsuits are still in the early stages, but litigation is beginning to take shape nationwide.

In February 2026, plaintiffs filed a motion to consolidate cases into a multidistrict litigation (MDL), alleging that Sanofi and Regeneron Pharmaceuticals failed to warn patients about a potential link between Dupixent (dupilumab) and cutaneous T-cell lymphoma (CTCL).

Key Updates:

• MDL Motion Filed: Plaintiffs are seeking to centralize Dupixent cases in federal court, which could streamline litigation and increase case filings.
• No Settlements or Trials Yet: There have been no jury verdicts or settlements to date.
• Wrongful Death Claims Emerging: The first wrongful death lawsuit was filed in late 2025, signaling potential expansion into more severe injury claims.
• Litigation Expected to Grow: As awareness increases and more patients are diagnosed, additional lawsuits are anticipated.

What This Means

The Dupixent litigation is still developing, and outcomes remain uncertain. While no court decisions have been reached yet, the push for MDL consolidation suggests the litigation may expand significantly in the coming months.

Contact Us Today for a FREE Consultation

If you or a loved one has experienced health complications due to Dupixent, don’t wait to seek legal help.

Contact Salenger, Sack, Kimmel & Bavaro today for a FREE consultation.

Call (800) 675-8556 or contact us online to get started. 

Why Are Dupixent Lawsuits Being Filed?

Dupixent lawsuits allege that drug manufacturers:

• Failed to warn patients about cancer risks
• Continued marketing the drug despite emerging safety concerns
• Did not adequately study long-term effects

Litigation is still in the early stages, and while there is no MDL or settlement yet, the number of claims is expected to grow.

Who May Qualify for a Dupixent Lawsuit?

You may be eligible if you:

• Used Dupixent (dupilumab)
• Were later diagnosed with CTCL or another T-cell lymphoma
• Experienced worsening skin or systemic symptoms
• Have medical records confirming diagnosis and treatment

Even if you are unsure, a case review can help determine eligibility.

What Compensation May Include

A successful Dupixent lawsuit may recover damages for:

• Medical expenses (past and future)
• Lost income or reduced earning capacity
• Pain and suffering
• Loss of quality of life
• Wrongful death (in fatal cases)

Why Choose Salenger, Sack, Kimmel & Bavaro – Our Experience in Dangerous Drug Litigation

• Decades of success in dangerous drug and product liability lawsuits
• No upfront fees – we only get paid if you win
• Access to top medical experts in oncology and dermatology
• Compassionate, personalized legal support for every client

Frequently Asked Questions (FAQs) About The Dupixent Lawsuit

Does Dupixent cause cancer?
Research has linked Dupixent (dupilumab) to an increased risk of Cutaneous T-Cell Lymphoma (CTCL), a rare type of skin cancer. Studies published in JAMA Dermatology (2024) and JAAD (2019) reported significantly higher CTCL risks among Dupixent users.

Recent data from 2025 further supports these findings, indicating a statistically significant association between Dupilumab exposure and T-cell lymphoma development.

Is there a Dupixent lawsuit?
Yes. Lawsuits are being filed against Sanofi and Regeneron, alleging they failed to warn patients about the risk of CTCL and other lymphomas. These cases are currently being evaluated for potential consolidation in federal court as of late 2025.

What cancers are linked to Dupixent?
The strongest evidence links Dupixent to Cutaneous T-Cell Lymphoma (CTCL), including subtypes like mycosis fungoides and Sézary syndrome. Some studies suggest an increased risk of other T-cell and NK-cell lymphomas as well.

Has Dupixent been recalled?
As of now, Dupixent has not been recalled by the FDA; however, label revisions and post-marketing monitoring requirements have been expanded to address emerging oncology concerns.

Am I eligible for a Dupixent lawsuit?
You may qualify if you:

• Took Dupixent (as prescribed)

• Were later diagnosed with CTCL or another T-cell lymphoma

• File your claim within your state’s statute of limitations

What compensation can I recover in a Dupixent lawsuit?
Potential damages include medical costs, lost wages, pain and suffering, and in severe cases, wrongful death compensation.

Speak With a Dupixent Lawsuit Lawyer Today

If you developed CTCL or another lymphoma after taking Dupixent, it may be worth exploring your legal options.

📞 Call (800) 675-8556 or fill out our online form today for a free, confidential consultation.